OncoCyte Corporation Income Statement 2025-2011 | OCX

Brief overview of profit and loss at OncoCyte Corporation

The overview follows changes across a five-year period. According to figures from OncoCyte Corporation, revenue changed from 1.2 million dollars to 4.1 million dollars over five years. Overall revenue changed by +233.5%, equal to an annualized rate of about 27.2%. Sales grew at a rate typical of a strong expansion phase.

Gross profit was −$639 thousand at the start and $2.3 million at the end of the period (+459.6%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from −52.5% to 56.7%. A wider margin shows that the economics of the core business improved.

EBITDA was −$31.8 million at the beginning and −$48.9 million at the end of the period (−53.7%). EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −2617% to −1206.6%. The business generated more EBITDA from each unit of revenue.

Across the five years, the net result shifted from −$29.9 million to −$50.2 thousand. The loss narrowed, although sustainable profitability has not yet returned.

Overall conclusion

The results present an uneven picture without one dominant signal. The constructive conclusion rests on higher operating efficiency, improving gross profitability and sales growth. The weaker side of the profile includes a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.